Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02

BACKGROUND: Vorinostat, a histone deacetylase (HDAC) inhibitor, has shown radiosensitizing properties in preclinical studies. This open-label, single-arm trial evaluated the maximum tolerated dose (MTD; phase I) and efficacy (phase II) of vorinostat combined with standard chemoradiation in newly dia...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Galanis, Evanthia, Anderson, S Keith, Miller, C Ryan, Sarkaria, Jann N, Jaeckle, Kurt, Buckner, Jan C, Ligon, Keith L, Ballman, Karla V, Moore, Dennis F, Nebozhyn, Michael, Loboda, Andrey, Schiff, David, Ahluwalia, Manmeet Singh, Lee, Eudocia Q, Gerstner, Elizabeth R, Lesser, Glenn J, Prados, Michael, Grossman, Stuart A, Cerhan, Jane, Giannini, Caterina, Wen, Patrick Y
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5909661/
https://ncbi.nlm.nih.gov/pubmed/29016887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox161
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados